Management of DME with MicroPulse® Laser Therapy
Dr. Lawrence S. Morse
Thursday, July 5, 2018
Tweet
Transcript
Embed
Email
Bookmark
<<
<
>
>>
Tweet
Facebook
Email
Chapters
Introduction
Diabetes is increasing in prevalence in the USA
Key Points
Historical Treatment: Laser
Before Focal Laser Rx
After Focal Laser Rx
ETDRS DME Results
Complications of Macular Laser
New Treatments: Lucentis: Anti-VEGF
Mean Change in VA at 36 Months
MicroPulse Laser Technology
IRIDEX MicroPulse stimulates intracellular biological factors
Photothermal stimulation with IRIDEX MicroPulse may facilitate HSP70 expression in the RPE without inducing lethal cellular damage
MicroPulse = Clinical Efficacy without Lethal Damage
MicroPulse ≠ Subthreshold Continuous-Wave
Biological Effects of MicroPulse
Importance of Low-Intensity, High-Density Laser
IQ 577 Laser with TxCell™ Scanning Laser Delivery System
MicroPulse Clinical Results – Lavinsky1
MicroPulse Laser and Anti-VEGF Therapy for DME
MicroPulse as an Adjunct to Anti-VEGF Therapy
Methods
MicroPulse Laser Settings: IQ 577™ IRIDEX
Timing of MicroPulse Laser Therapy
Baseline Characteristics
Visual Effects of Treatments
OCT Effects of Treatments
Number of Injections for Treatment Groups
Example of MicroPulse + Lucentis at LFU
Conclusions
MicroPulse Expectations
MicroPulse Take Home Message
Case 1: MicroPulse Monotherapy - DME
Case 2: MicroPulse Monotherapy - DME
Case 3: MicroPulse as Adjunct to Anti-VEGF - DME
Case 4: MicroPulse as Adjunct to Anti-VEGF Neovascular Age-Related Macular Degeneration
Case 5: MicroPulse Monotherapy Bilateral Central Serous Chorioretinopathy
No transcript for this webinar
Request Info